臨床婦人科産科71巻10号

2017年10月発行

今月の臨床 最新！　婦人科がん薬物療法─化学療法薬から分子標的薬・免疫療法薬まで

卵巣がん

PARP阻害薬の現況と展望

著者： 関根正幸¹ 榎本隆之¹

所属機関： ¹新潟大学大学院医歯学総合研究科産科婦人科学教室

ページ範囲：P.924 - P.934

文献概要

●BRCA変異陽性のプラチナ感受性再発卵巣がんを対象にオラパリブ維持療法の有効性を示したSOLO2の結果を受け，オラパリブは医薬品医療機器総合機構（PMDA）に承認申請が行われている．

●最近の臨床試験では，相同組換え修復異常（homologous recombination deficiency : HRD）を示す腫瘍に対して対象が拡大されている．

●ルカパリブ維持療法の有効性を示したARIEL3の結果では，BRCA変異とHRDのステータスに関係なく，プラチナ感受性再発症例に有効性が示唆されている．

参考文献

1）De Vos M, et al : The diverse roles and clinical relevance of PARPs in DNA damage repair : current state of the art. Biochem Pharmacol 84 : 137─146, 2012

2）Helleday T, et al : Poly（ADPribose）polymerase（PARP-1）in homologous recombination and as a target for cancer therapy. Cell Cycle 4 : 1176─1178, 2005

3）Dantzer F, et al : Involvement of poly（ADP-ribose） polymerase in base excision repair. Biochimie 81 : 69─75, 1999

4）Jubin T, et al : The PARP family : insights into functional aspects of poly（ADP-ribose）polymerase-1 in cell growth and survival. Cell Prolif 49 : 421─437, 2016

5）Venkitaraman AR : Cancer suppression by the chromosome custodians, BRCA1 and BRCA2. Science 343 : 1470─1475, 2014

6）Plummer E, et al : Targeting poly（ADP-ribose） polymerase : a two-armed strategy for cancer therapy. Clin Cancer Res 13 : 6252─6256, 2007

7）Murai J, et al : Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72 : 5588─5599, 2012

8）Konstantinopoulos P, et al : Homologous recombination deficiency : exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov 5 : 1137─1154, 2015

9）Audeh M, et al : Oral poly（ADP-ribose） polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer : a proof-of-concept trial. Lancet 376 : 245─251, 2010

10）Gelmon K, et al : Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer : a phase 2, multicentre, open-label, nonrandomized study. Lancet Oncol 12 : 852─861, 2011

11）Ledermann J, et al : Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366 : 1382─1392, 2012

12）Ledermann J, et al : Olaparib maintenance therapy in patients with platinum sensitive relapsed serous ovarian cancer : a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15 : 852─861, 2014

13）Ledermann J, et al : Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving Olaparib maintenance monotherapy : an updated analysis from a randomized, placebo-controlled double-blind, phase 2 trial. Lancet Oncol 17 : 1579─1589, 2016

14）Kaye S, et al : Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly（ADP-ribose） polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 30 : 372─379, 2012

15）Bixel K, et al : Olaparib in the management of ovarian cancer. Pharmgenomics Pers Med 8 : 127─135, 2015

16）The Society of Gynecologic Oncology（SGO）Annual Meeting on Women's Cancer 2017 https://sgo.confex.com/sgo/2017/meetingapp.cgi/Paper/8718

17）Pujade-Lauraine E, et al : Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation（SOLO2/ENGOT-Ov21） : a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. pii : S1470─2045（17）30469─2.（doi:10.1016/S1470─2045（17）30469─2）

18）Mirza M, et al : Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375 : 2154─2164, 2016

19）Swisher E, et al : Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma（ARIEL2 Part 1） : an international, multicentre open-label, phase 2 trial. Lancet Oncol 18 : 75─87, 2016

20）Kristeleit R, et al : Final results of ARIEL2（Part 1） : a phase 2 trial to prospectively identify ovarian cancer（OC） responders to Rucaparib using tumor genetic analysis. Eur J Can 51 : S531, 2015

21）Press release 19 June 2017 ; http://clovisoncology.com

22）Coleman R, et al : A phase II evaluation of the potent, hightly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation-an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 137 : 386─391, 2015

23）Oza A, et al : Olaparib combined with chemotherapy for recurrent platinumsensitive ovarian cancer : a randomised phase 2 trial. Lancet Oncol 16 : 87─97, 2015

24）Kummar S, et al : Randomized trial of oral cyclophosphamide and Veliparib in highgrade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clin Cancer Res 21 : 1574─1582, 2015

25）Liu JF, et al : A Phase 1 trial of the poly（ADP-ribose） polymerase inhibitor olaparib（AZD2281） in combination with the anti-angiogenic cediranib（AZD2171） in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer 49 : 2972─2978, 2013

26）Liu JF, et al : Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer : a randomised phase 2 study. Lancet Oncol 15 : 1207─1214, 2014

27）Liu, et al : PARP inhibitors in ovarian cancer : current status and future promise. Gynecol Oncol 133 : 362─369, 2014

28）日本医学会「医療における遺伝学的検査・診断に関するガイドライン」2011（http://jams.med.or.jp/guideline/genetics-diagnosis.pdf）

29）Evans T, et al : PARP inhibitors in ovarian cancer : evidence, experience and clinical potential. Ther Adv Med Oncol 9 : 253─267, 2017

30）Norquist B, et al : Secondary somatic mutations restoring B1〜CAI/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 29 : 3008─3015, 2011

31）Johnson N, et al : Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proc Natl Acad Sci U S A 110 : 17041─17046, 2013

32）Cao L, et al : A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. Mol Cell 35 : 534─541, 2009

33）Jaspers JE, et al : Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov 3 : 68─81, 2013

34）Dumitriu IE, et al : UV irradiation inhibits ABC transporters via generation of ADP-ribose by concerted action of poly（ADP-ribose）polymerase-1 and glycohydrolase. Cell Death Differ 11 : 314─320, 2004

35）Rottenberg S, et al : High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 105 : 17079─17084, 2008

36）Pennington KP, et al : Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallo-pian tube, and peritoneal carcinomas. Clin Cancer Res 20 : 764─775, 2014

37）Abkevich V, et al : Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 107 : 1776─1782, 2012

38）Timms KM, et al : Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res 16 : 475, 2014